AKBA Akebia Therapeutics Inc
Price (delayed)
$1.35
Market cap
$283.89M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.21
Enterprise value
$288.72M
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is
Highlights
Akebia Therapeutics's EPS has soared by 61% YoY and by 9% from the previous quarter
AKBA's net income has soared by 59% YoY and by 6% from the previous quarter
AKBA's debt is down by 18% year-on-year but it is up by 17% since the previous quarter
The company's quick ratio fell by 37% QoQ and by 18% YoY
The equity is down by 26% year-on-year and by 24% since the previous quarter
Key stats
What are the main financial stats of AKBA
Market
Valuations
Earnings
Shares outstanding
210.29M
Market cap
$283.89M
Enterprise value
$288.72M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.62
EV/EBIT
N/A
EV/EBITDA
24.35
EV/Sales
1.65
Revenue
$174.5M
EBIT
-$32.97M
EBITDA
$11.86M
Free cash flow
-$39M
Per share
Balance sheet
Liquidity
EPS
-$0.21
Free cash flow per share
-$0.19
Book value per share
-$0.16
Revenue per share
$0.83
TBVPS
$0.68
Total assets
$220.2M
Total liabilities
$253.95M
Debt
$44.33M
Equity
-$33.75M
Working capital
$4.8M
Debt to equity
-1.31
Current ratio
1.04
Quick ratio
0.65
Net debt/EBITDA
0.41
Margins
Efficiency
Dividend
EBITDA margin
6.8%
Gross margin
62.6%
Net margin
-23.2%
Operating margin
-17.5%
Return on assets
-17.5%
Return on equity
N/A
Return on invested capital
-61.5%
Return on capital employed
-29.2%
Return on sales
-18.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AKBA stock price
How has the Akebia Therapeutics stock price performed over time
Intraday
-2.17%
1 week
-12.9%
1 month
9.76%
1 year
8%
YTD
8.87%
QTD
32.35%
Financial performance
How have Akebia Therapeutics's revenue and profit performed over time
Revenue
$174.5M
Gross profit
$109.17M
Operating income
-$30.61M
Net income
-$40.44M
Gross margin
62.6%
Net margin
-23.2%
The operating income has surged by 64% year-on-year
The operating margin has soared by 59% YoY but it has contracted by 7% from the previous quarter
AKBA's net income has soared by 59% YoY and by 6% from the previous quarter
AKBA's net margin has surged by 53% year-on-year
Growth
What is Akebia Therapeutics's growth rate over time
Valuation
What is Akebia Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
1.62
EV/EBIT
N/A
EV/EBITDA
24.35
EV/Sales
1.65
Akebia Therapeutics's EPS has soared by 61% YoY and by 9% from the previous quarter
The equity is down by 26% year-on-year and by 24% since the previous quarter
The price to sales (P/S) is 16% more than the last 4 quarters average of 1.4
Akebia Therapeutics's revenue has decreased by 13% YoY and by 7% QoQ
Efficiency
How efficient is Akebia Therapeutics business performance
Akebia Therapeutics's ROS has soared by 58% YoY and by 2.1% from the previous quarter
The return on invested capital is up by 47% year-on-year and by 5% since the previous quarter
The ROA has grown by 41% YoY and by 2.8% from the previous quarter
Dividends
What is AKBA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AKBA.
Financial health
How did Akebia Therapeutics financials performed over time
AKBA's total assets is 13% smaller than its total liabilities
Akebia Therapeutics's current ratio has decreased by 39% QoQ and by 19% YoY
The company's quick ratio fell by 37% QoQ and by 18% YoY
The debt to equity has increased by 35% year-on-year and by 6% since the previous quarter
The equity is down by 26% year-on-year and by 24% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.